Search results
Results From The WOW.Com Content Network
In April 2019, following a large-scale ring-vaccination scheme in the DRC outbreak, the WHO published the preliminary results of its research, in association with the DRC's Institut National pour la Recherche Biomedicale, into the effectiveness of the ring vaccination program, stating that the rVSV-ZEBOV-GP vaccine had been 97.5% effective at stopping Ebola transmission, relative to no ...
Ebola vaccines are vaccines either approved or in development to prevent Ebola. ... Other common side-effects were pain at the site of injection, myalgia, ...
In January 2014, Tekmira started a Phase I clinical trial of TKM-Ebola to assess its safety in healthy people with a dose of 0.24 mg/kg/day for seven day treatments. The FDA placed the trial on clinical hold in July 2014 to assess results, after some subjects had flu-like responses. [ 6 ]
In the original clinical trials for Pfizer-BioNTech's COVID-19 vaccine, for example, less than half of study participants reported side effects, but the shot worked well for the vast majority of ...
The Ebola virus devastated west Africa in 2014, claiming over 11,000 lives in Sierra Leone, Liberia and Guinea. Ebola: How a vaccine turned a terrifying virus into a preventable disease Skip to ...
According to the U.S. Centers for Disease Control and Prevention, while "any vaccine can cause side effects", [11] most side effects are minor, primarily including sore arms or a mild fever. [11] Unlike most medical interventions vaccines are given to healthy people, where the risk of side effects is not as easily outweighed by the benefit of ...
RSV vaccine side effects in older adults . The CDC lists the following as possible side effects of the RSV vaccine: Pain, redness, and swelling where the shot is given. Fatigue. Fever. Headache ...
There is also a version called GamEvac which is a homologous Ad5-vectored vaccine. [1] GamEvac-Combi was developed by Gamaleya Research Institute of Epidemiology and Microbiology . As of 2015 [update] the vaccine has been licensed in Russia for emergency use, on the basis of Phase 1 and Phase 2 clinical trials.